KR20080109075A - 헤테로사이클릭 ｇｐｃｒ 작용제 - Google Patents

헤테로사이클릭 ｇｐｃｒ 작용제 Download PDF

Info

Publication number
KR20080109075A
KR20080109075A KR1020087027271A KR20087027271A KR20080109075A KR 20080109075 A KR20080109075 A KR 20080109075A KR 1020087027271 A KR1020087027271 A KR 1020087027271A KR 20087027271 A KR20087027271 A KR 20087027271A KR 20080109075 A KR20080109075 A KR 20080109075A
Authority
KR
South Korea
Prior art keywords
formula
compound
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087027271A
Other languages
English (en)
Korean (ko)
Inventor
리사 사라 버트램
매튜 콜린 토르 파이프
마틴 제임스 프록터
제프리 마틴 윌리암스
Original Assignee
프로시디온 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606913A external-priority patent/GB0606913D0/en
Priority claimed from GB0700112A external-priority patent/GB0700112D0/en
Application filed by 프로시디온 리미티드 filed Critical 프로시디온 리미티드
Publication of KR20080109075A publication Critical patent/KR20080109075A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020087027271A 2006-04-06 2007-04-05 헤테로사이클릭 ｇｐｃｒ 작용제 Ceased KR20080109075A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0606913A GB0606913D0 (en) 2006-04-06 2006-04-06 Compounds
GB0606913.2 2006-04-06
GB0700112A GB0700112D0 (en) 2007-01-04 2007-01-04 Compounds
GB0700112.6 2007-01-04

Publications (1)

Publication Number Publication Date
KR20080109075A true KR20080109075A (ko) 2008-12-16

Family

ID=38227799

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087027271A Ceased KR20080109075A (ko) 2006-04-06 2007-04-05 헤테로사이클릭 ｇｐｃｒ 작용제

Country Status (12)

Country Link
US (1) US20090221639A1 (enExample)
EP (1) EP2013201B1 (enExample)
JP (1) JP2009532453A (enExample)
KR (1) KR20080109075A (enExample)
AU (1) AU2007235673A1 (enExample)
BR (1) BRPI0710839A2 (enExample)
CA (1) CA2646676A1 (enExample)
MX (1) MX2008012814A (enExample)
NO (1) NO20084307L (enExample)
NZ (1) NZ571869A (enExample)
WO (1) WO2007116229A1 (enExample)
ZA (1) ZA200809289B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016507B1 (ru) * 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
GB0700125D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EP2114933B1 (en) * 2007-01-04 2011-09-07 Prosidion Ltd Piperidine gpcr agonists
CL2008000018A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2010539152A (ja) * 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
ES2499018T3 (es) 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CA2724426A1 (en) * 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
ES2403120T3 (es) 2008-12-24 2013-05-14 Cadila Healthcare Limited Nuevos derivados de oxima
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
BR112012002311A2 (pt) 2009-08-05 2016-05-31 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso do composto.
BR112012002293A2 (pt) * 2009-08-05 2016-06-14 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso do composto
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
SG188547A1 (en) 2010-10-08 2013-04-30 Cadila Healthcare Ltd Novel gpr 119 agonists
SG189320A1 (en) 2010-10-14 2013-05-31 Daiichi Sankyo Co Ltd Acylbenzene derivative
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
PH12014500251A1 (en) 2011-07-29 2014-03-17 Daiichi Sankyo Co Ltd N-hetero-ring-substituted amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013062837A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Piperidine derivatives useful as gpr119 agonists
HK1200824A1 (en) * 2012-01-18 2015-08-14 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2015523404A (ja) 2012-08-02 2015-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6856094A (en) * 1994-06-01 1995-12-21 Yamanouchi Pharmaceutical Co., Ltd. Oxadiazole derivative and medicinal composition thereof
US6699853B2 (en) * 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
DE60022386T2 (de) * 1999-12-16 2006-06-22 Schering Corp. Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
EP4101846B1 (en) * 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US8207147B2 (en) * 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
JP2008545010A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists

Also Published As

Publication number Publication date
WO2007116229A1 (en) 2007-10-18
ZA200809289B (en) 2012-06-27
NO20084307L (no) 2008-10-28
NZ571869A (en) 2011-11-25
JP2009532453A (ja) 2009-09-10
MX2008012814A (es) 2008-10-17
BRPI0710839A2 (pt) 2011-08-23
CA2646676A1 (en) 2007-10-18
US20090221639A1 (en) 2009-09-03
EP2013201A1 (en) 2009-01-14
WO2007116229A8 (en) 2007-12-27
EP2013201B1 (en) 2012-07-25
AU2007235673A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
EP2013201B1 (en) Heterocyclic gpcr agonists
JP4958560B2 (ja) Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
JP5114395B2 (ja) Ｇｐｃｒアゴニスト
JP4916452B2 (ja) Ｇｐｃｒ作動薬としてのピリジン、ピリミジン、およびピラジンの誘導体
JP4980928B2 (ja) Ｇタンパク質共役受容体（ｇｐｒ１１６）作動薬および肥満および糖尿病治療のためのその使用
JP2008545008A (ja) Ｇｐｃｒアゴニスト
US20090203676A1 (en) G-protein Coupled Receptor Agonists
US20100286110A1 (en) Azetidinyl g-protein coupled receptor agonists
JP2010514832A (ja) ピペリジンｇｐｃｒアゴニスト
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
JP2010514828A (ja) ピペリジンｇｐｃｒアゴニスト
JP2008525417A (ja) Ｇタンパク質結合受容体作動薬
JP2010514830A (ja) ピペリジンｇｐｃｒアゴニスト
JP2010514831A (ja) ピペリジンｇｐｃｒアゴニスト
JP2010514829A (ja) ピペリジンｇｐｃｒアゴニスト
CN101287729A (zh) Gpcr激动剂
CN101252929A (zh) G蛋白偶联受体激动剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120404

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130923

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131224

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130923

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I